AUS
NZ
UK
CA
USA
IND
Broker Panmure Liberum has reiterated its favorable rating on Scancell Holdings PLC (LSE:SCLP) shares, maintaining a target price of 23.3p in light of Scancell’s recent strategic partnership with PharmaJet. The collaboration is set to utilize PharmaJet’s Stratis needle-free intramuscular (IM) injection system for Scancell’s SCIB1/iSCIB1+ DNA cancer vaccine. This move aims to ensure a seamless transition into the anticipated Phase 2/3 clinical trials, scheduled to begin in 2025.
Scancell’s choice of PharmaJet’s advanced delivery system is a significant step in the development of its cancer vaccine, reflecting a commitment to optimizing the administration process. The needle-free technology is expected to facilitate easier and more efficient vaccine delivery, which could be crucial for the upcoming clinical trials. This partnership underscores Scancell’s focus on enhancing its vaccine delivery mechanisms, which could play a pivotal role in the trial’s success.
Panmure Liberum remains optimistic about the potential impact of the clinical data that Scancell is expected to release in late 2024 and early 2025. The broker anticipates that the results will be both value-enhancing and beneficial in elevating Scancell’s profile within the cancer vaccine sector. This is particularly relevant given the recent surge in interest in cancer vaccines, which has heightened the market’s focus on promising new treatments.
The positive clinical data anticipated from Scancell’s trials could significantly boost the company's standing in the biotech industry. This, in turn, may enhance Scancell’s ability to secure funding for future pivotal clinical trials or explore out-licensing opportunities. Panmure Liberum’s assessment reflects a belief that the upcoming results will provide substantial momentum for Scancell, positioning the company favorably for future endeavors.
Overall, the collaboration with PharmaJet is seen as a strategic move that aligns with Scancell’s broader goals of advancing its cancer vaccine programs. The anticipated clinical trials and the subsequent data releases are expected to drive significant interest and support for Scancell’s initiatives, reinforcing its potential as a key player in the cancer vaccine market.
